arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GENELUX Corp

GNLX
$1.81 ▼ -0.15 (-7.40%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

GENELUX Corp faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $81.4M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -47.3% ↘
FCF / Share $-0.18 ↘
Trailing P/E —
Price / Book 5.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-8.93M
↓ -19.2% —
FCF / Share Free cash flow per share
$-0.18
↓ -12.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 5 years · 19 quarters